Clinical Trials Logo

Fibrosis clinical trials

View clinical trials related to Fibrosis.

Filter by:

NCT ID: NCT03850145 Completed - Cystic Fibrosis Clinical Trials

Educational Program Through Video Conference for Inhaled Therapies in Cystic Fibrosis Patients

Visio-Respir
Start date: February 1, 2019
Phase:
Study type: Observational

Educational programs are essential for cystic fibrosis patients who need to take several different drugs every day. Compliance is often klow in these patients, and clinicals and paramedics try to increase it, through educational programs. As for inhaled therapies, the CF center of Montpellier uses a video conference tool to educate patients. The program may involve either the physiotherapist or the doctor or both. Through the present study, the investigators would like to evaluate the current practice at the CF center of Montpellier and verify if patients feel that the physiotherapist could handle the program on his own, without the support of a physician.

NCT ID: NCT03846843 Completed - Cirrhosis Clinical Trials

OCR002-SP103 - Oral Immediate Release Study

Start date: August 15, 2016
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1, 2-part, crossover study in approximately 33 adult subjects (12 subjects in Part 1 and 21 subjects in Part 2), with varying degrees of cirrhosis with analysis of pharmacokinetic (PK) data after Part 1 to guide dose regimen selection and PK sampling time points for OCR-002 in Part 2.

NCT ID: NCT03843723 Completed - Cystic Fibrosis Clinical Trials

Cystic Fibrosis and Fit-to-Fly

CyFF
Start date: March 1, 2019
Phase:
Study type: Observational

Due to the hypobaric hypoxia during air travel, some patients with Cystic Fibrosis (CF) need supplemental oxygen during air travel. The study aims to evaluate if adding exercise desaturation to the pre-flight evaluation will help predict requirements for in-flight supplemental oxygen.

NCT ID: NCT03837444 Completed - Cirrhosis Clinical Trials

Microvesicles and Monocytes to Predict Mortality of Patients With Cirrhosis

PROMICE
Start date: June 12, 2019
Phase:
Study type: Observational

Chronic liver diseases related to viral hepatitis, metabolic syndrome or excessive alcohol consumption can evolve towards cirrhosis. Cirrhosis is responsible for 170 000 deaths per year in Europe. Initially asymptomatic and called "compensated" it can become "decompensated" with the developement of acute complications such as infections, ascites or variceal bleeding. The transition from compensated to decompensated cirrhosis is associated with a reduction in survival from 95 to 55% at 1 year. The only curative treatment for cirrhosis is liver transplantation (LT). Liver transplants are allocated according to the severity of the patients. Despite a modest prognostic value (area under the ROC curve = 0.7 to predict the risk of death), graft allocation is based on the MELD (Model for End-Stage Liver Disease) score including INR, bilirubin and serum creatinine. In 2014, 11.5% of registered patients died on the liver transplant waiting list, illustrating the need for biomarkers that predict death and improve MELD-based prediction. Microvesicles are membrane vesicles released in extracellular space during cell activation or apoptosis. Our team showed that circulating levels of hepatocyte microvesicles increase with the severity of cirrhosis and predict survival at 6 months independently of MELD score in a cohort of 242 patients with cirrhosis. Type 1 interferons (IFN-1) are mediators of inflammation, which is excessively activated in cirrhosis. Our team has shown that a gene signature (IFN score) measured in the immune cells of 101 patients with cirrhosis is able to predict 6 month-survival independently of the MELD score. Thus, the investigators hypothesize that a composite score combining the level of circulating hepatocyte microvesicles, the IFN score and the MELD score could improve the prediction of survival in patients with severe cirrhosis. The aim of this study is to compare the prognostic performance for the cumulative incidence of death at 6 months of a composite score including MELD, hepatocyte microvesicle level and IFN score with that of the MELD score alone, in patients with Child B or C cirrhosis, considering liver transplantation as a competitive risk. To address this question, peripheral blood from 335 patients with Child B or C cirrhosis will be obtained and hepatocyte microvesicle levels and IFN score will be measured using ELISA/filtration and Real Time-quantitative PCR.

NCT ID: NCT03832946 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis (IPF)

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.

NCT ID: NCT03820349 Completed - Cystic Fibrosis Clinical Trials

Cystic Fibrosis and Cognitive Function

Start date: May 7, 2018
Phase:
Study type: Observational

The long-term goal of this project is to examine the effects of cystic fibrosis (CF) and cystic fibrosis related diabetes (CFRD) on brain structure and function

NCT ID: NCT03819400 Completed - Kidney Graft Clinical Trials

Evaluation of Kidney Graft's Fibrosis With Real Time Shear-wave Elastography

Elastogreffe
Start date: March 29, 2019
Phase:
Study type: Observational

Kidney graft's fibrosis is correlated with prognostic of kidney's graft, wathever the initial etiology. Actually, that evaluation is based on histologic score of Banff FI/AT (0 to III). It is obtained thanks to punction-biopsy, which is invasive and can lead complications. This exam is systematic on M3 of the transplantation. Tissue's fibrosis is a proliferation of extracellular matrix, leading to an increase of fibrosed tissue rigidity. Elastography is an ultrasound technique allowing evaluation of tissues' rigidity. The purpose is the validation of elastograhpy, innovative and non -invasive technique, and more specifically Shear Wave Elastography (SWE). For this, strain ratio (SR) could improve intra-operator variability and estimate fibrosis' degree of kidney's graft.

NCT ID: NCT03804593 Completed - Clinical trials for Hepatocellular Carcinoma

HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)

Start date: December 17, 2018
Phase:
Study type: Observational

This is a multi-center study to prospectively gather clinically-characterized plasma samples to determine the diagnostic performance characteristics (sensitivity and specificity) of the HCCBloodTest among patients with cirrhosis with and without HCC

NCT ID: NCT03801993 Completed - Cystic Fibrosis Clinical Trials

Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis

GALAXY
Start date: May 1, 2019
Phase:
Study type: Observational

This is a prospective, multicenter, observational study designed to collect gastrointestinal related data in patients with Cystic Fibrosis (CF).

NCT ID: NCT03800459 Completed - Cystic Fibrosis Clinical Trials

Effect of a Family Empowerment Program on Coping, Problem Solving in Parents, and Quality of Life in Children With Cystic Fibrosis

Start date: December 14, 2016
Phase: N/A
Study type: Interventional

Parents of children with cystic fibrosis (CF) experience high levels of stress and problems. Family empowerment interventions provide important support for many patients with CF and their families. However,there is a lack of research exploring the effects of such empowerment programs on coping, and Problem Solving among parents, and Quality of Life in Children with CF. The present study aimed to assess the effect of a family empowerment program-based nursing intervention on parents coping with stress and problem solving, and quality of life children with CF.